TSX News -
Trillium Announces Pricing of US$30.0 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preference Shares
TORONTO, ONTARIO–(Marketwired – May 26, 2017) – Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for [...]